Viking Therapeutics Holds Annual Stockholders Meeting

Viking Therapeutics ( (VKTX) ) has provided an announcement.

On May 20, 2025, Viking Therapeutics held its Annual Meeting of Stockholders where approximately 68.3% of outstanding shares were represented. During the meeting, stockholders elected Matthew W. Foehr and Charles A. Rowland, Jr. as Class I directors until 2028, ratified CBIZ CPAs P.C. as the independent accounting firm for 2025, and approved executive compensation on an advisory basis.

The most recent analyst rating on (VKTX) stock is a Buy with a $102.00 price target. To see the full list of analyst forecasts on Viking Therapeutics stock, see the VKTX Stock Forecast page.

Spark’s Take on VKTX Stock

According to Spark, TipRanks’ AI Analyst, VKTX is a Neutral.

Viking Therapeutics’ overall score reflects the typical profile of an early-stage biotech company. Strengths include a robust balance sheet and promising clinical trial results, but these are offset by high operational losses and cash burn. Technical indicators suggest short-term positive momentum, yet valuation concerns persist due to the absence of profitability. The earnings call provided a positive outlook with significant pipeline advancements.

To see Spark’s full report on VKTX stock, click here.

More about Viking Therapeutics

Viking Therapeutics, Inc. operates in the biotechnology industry, focusing on the development of novel therapies for metabolic and endocrine disorders.

Average Trading Volume: 4,075,366

Technical Sentiment Signal: Hold

Current Market Cap: $3.03B

Learn more about VKTX stock on TipRanks’ Stock Analysis page.